• Skip to primary navigation
  • Skip to main content
  • Skip to footer

LKT Labs

Biochemicals for Life Science Research

  • Products
    • New Products
    • Cancer Biology
    • Cardiovascular
    • Endocrine Signaling and Immunology
    • Metabolic and GI Pathology
    • Microbiology
    • Natural Products
    • Neuroscience
    • Peptides
    • Pharmaceutical Impurities and Derivatives
    • Stem Cell Modulators
  • Services
    • Custom Synthesis
    • Natural Product Isolation
    • Analytical Services
  • Int’l Distributors
  • Support
    • About LKT Labs
    • General Inquiry
    • Bulk Quote Request
    • Document Request
    • Technical Support
    • Catalog Request
    • Product Flyers
  • Contact Us
  • Cart
  • Login / Register

RAF265

Product ID R0020
Cas No. 927880-90-8
Purity ≥98%
Product Unit SizeCostQuantityStock
1 mg $129.80 In stock
5 mg $389.50 In stock
Bulk Quote
Add to Wishlist

Quicklinks

  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Custom Order

Description

RAF265 is an orally bioavailable anticancer chemotherapeutic compound that inhibits primarily WT B-Raf, mutant (V600E) B-Raf, and VEGFR2, but is also active against c-Raf, PDGFR, CSF-1R, RET, c-Kit, Src, and STE20. This compound is in clinical trials as a treatment for unresectable or metastatic melanoma. Inhibition of B-Raf by RAF265 attenuates downstream ERK and RET signaling, preventing tumor cell proliferation. Raf265-induced alterations in ERK signaling also decreases expression of c-fos and NFATc1, inhibiting in vitro differentiation of PBMCs to osteoclasts and inhibiting osteoclast resorptive capacity, therefore inhibiting osteoclastogenesis.

Product Info

Cas No.

927880-90-8

Purity

≥98%

Formula

C24H16F6N6O

Formula Wt.

518.4

Chemical Name

1-methyl-5-(2-(5-(trifluoromethyl)-1H-imidazol-2-yl)pyridin-4-yloxy)-N-(4-(trifluoromethyl)phenyl)-1H-benzo[d]imidazol-2-amine

IUPAC Name

CN1C2=C(C=C(C=C2)OC3=CC(=NC=C3)C4=NC=C(N4)C(F)(F)F)N=C1NC5=CC=C(C=C5)C (F)(F)F

Solubility

DMSO 100 mg/mL (192.89 mM) Ethanol 33 mg/mL (63.65 mM) Water Insoluble

Shipping and Storage

Store Temp

-20°C

Ship Temp

Ambient

Downloads

MSDS

R0020 MSDS PDF

Info Sheet

R0020 Info Sheet PDF

Brochures

Ras-Raf-MEK-ERK Pathway Booklet

References

Garcia-Gomez A, Ocio EM, Pandiella A, et al. RAF265, a dual BRAF and VEGFR2 inhibitor, prevents osteoclast formation and resorption. Therapeutic implications. Invest New Drugs. 2013 Feb;31(1):200-5. d PMID: 22773056.

Huang T, Karsy M, Zhuge J, et al. B-Raf and the inhibitors: from bench to bedside. J Hematol Oncol. 2013 Apr 25;6:30. PMID: 23617957.

Su Y, Vilgelm AE, Kelley MC, et al. RAF265 inhibits the growth of advanced human melanoma tumors. Clin Cancer Res. 2012 Apr 15;18(8):2184-98. Erratum in: Clin Cancer Res. 2012 Aug 15;18(16):4475. PMID: 22351689.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Footer

  • Contact Us
  • About Us
  • Site Map
  • Terms and Conditions
LKT Laboratories, Inc.
545 Phalen Blvd.
St. Paul MN, 55130

Ph: (888)-558-5227
Fax: (888)-558-7329

©2023 LKT Laboratories, All Rights Reserved - Products for research use only